Vertex Pharmaceuticals Incorporated VRTX
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) P/B ratio
As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/B ratio of 6.6×. Over the past ten years it has ranged from 4.8× (October 2021) to 32.6× (April 2015); the current reading is higher than 37% of that period. That is above the Biotechnology industry median of 2.5× and above the Healthcare sector median of 2.5×.
P/B ratio, daily
Annual
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 6.2× | (1.87%) |
| FY2024 | 6.3× | 5.08% |
| FY2023 | 6.0× | 14.40% |
| FY2022 | 5.3× | (6.03%) |
| FY2021 | 5.6× | (20.73%) |
| FY2020 | 7.1× | (23.47%) |
| FY2019 | 9.2× | (2.79%) |
| FY2018 | 9.5× | (49.01%) |
| FY2017 | 18.6× | 36.07% |
| FY2016 | 13.7× | (50.68%) |
Quarterly
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 6.2× | 6.20% |
| Mar 2026 | 5.9× | (5.64%) |
| Dec 2025 | 6.2× | 7.45% |
| Sep 2025 | 5.8× | (13.13%) |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | 2.6× |
| RPRX Royalty Pharma PLC compare | 2.6× |
| VRTX Vertex Pharmaceuticals Incorporated | 6.6× |
| ARGX argenex SE compare | 7.1× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 7.8× |
| MRNA Moderna, Inc. compare | 11.7× |
| RVMD Revolution Medicines, Inc. compare | 16.6× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 25.3× |
| INSM Insmed, Inc. compare | 33.8× |
| Biotechnology industry median | 2.5× |
| Healthcare sector median | 2.5× |
| Market median | 1.8× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement